DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome

Haematologica. 2023 Jun 1;108(6):1463-1467. doi: 10.3324/haematol.2022.282025.

Authors

Kerry J Savage¹, Graham W Slack²

Affiliations

¹ Centre for Lymphoid Cancer, BC Cancer; University of British Columbia and Division of Medical Oncology, BC Cancer. ksavage@bccancer.bc.ca.
² Centre for Lymphoid Cancer, BC Cancer; University of British Columbia and Department of Pathology, BC Cancer.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anaplastic Lymphoma Kinase / genetics
Dual-Specificity Phosphatases / genetics
Humans
Lymphoma, Large-Cell, Anaplastic* / genetics
Lymphoma, Large-Cell, Anaplastic* / pathology
Mitogen-Activated Protein Kinase Phosphatases / genetics
Receptor Protein-Tyrosine Kinases

Substances

Receptor Protein-Tyrosine Kinases
Anaplastic Lymphoma Kinase
DUSP22 protein, human
Dual-Specificity Phosphatases
Mitogen-Activated Protein Kinase Phosphatases